U.S. markets closed

Vyant Bio, Inc. (VYNT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.95000.0000 (0.00%)
At close: 4:00PM EDT
2.8300 -0.12 (-4.07%)
After hours: 07:32PM EDT

Vyant Bio, Inc.

Two Executive Campus
2370 State Route 70 West Suite 310
Cherry Hill, NJ 08002
United States
201 479 1357
http://www.vyantbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees77

Key Executives

NameTitlePayExercisedYear Born
Mr. Andrew D.C. LaFrence CPA, CPACFO & COO106.07kN/A1963
Mr. Yung-Ping Yeh M.B.A., M.S., P.M.P.Chief Innovation Officer & Director210.33kN/AN/A
Dr. Robert J. PetcavichChief Science Advisor & Director212.48kN/A1954
Mr. John A. Roberts M.B.A., MBAPres, CEO & DirectorN/AN/A1959
Dr. Ralf BrandtPres of Discovery & Early Devel. ServicesN/AN/A1967
Dr. Barb Jones Ph.D.Sr. VP of External & Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company, through its subsidiary, StemoniX, develops and manufactures at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. StemoniX, through collaborations with drug discovery organizations, tests compounds in-house, creates cell-based disease models, and operationalizes custom human iPSC-derived disease models for high-throughput screening. The company, through its subsidiary, vivoPharm, offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm specializes in conducting studies to guide drug development, starting from compound libraries and ending with a set of in vitro and in vivo data and reports, as needed for investigational new drug filings. The company is based in Cherry Hill, New Jersey.

Corporate Governance

Vyant Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.